Minutes of Implanet’s Annual General Meeting Held on June 9, 2022

Rhea-AI Summary

IMPLANET, a medical technology company, held its Annual General Meeting on June 9, 2022, with a quorum of 26.96%, represented by 5,305,617 shares. All resolutions were adopted. Upcoming financial events include H1 2022 revenue on July 11 and H1 2022 results on September 20. Founded in 2007, IMPLANET specializes in vertebral implants and reported a consolidated revenue of €6.1 million in 2021. They have received FDA clearance and CE mark for their JAZZ® product, reflecting their commitment to improving spinal treatment.

Positive

• All resolutions at the Annual General Meeting were adopted.
• The company reported a consolidated revenue of €6.1 million in 2021.

Negative

• The quorum of the Annual General Meeting was only 26.96%, indicating limited shareholder engagement.

BORDEAUX, France & BOSTON--(BUSINESS WIRE)-- Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral implants, informs its shareholders that its Annual General Meeting was held on Thursday 9 June 2022 at 2:00 pm at the company's registered office in Martillac.

The number of shares held by the shareholders present or represented was 5,305,617, representing a quorum of 26.96%.

All the resolutions of this Annual General Meeting were adopted.

The minutes of the shareholders' meeting will be available within the legal deadlines on the Company's website: www.implanet-invest.com/general-meeting

Upcoming financial events:

- H1 2022 revenue, July 11, 2022, after market
- H1 2022 results, September 20, 2022, after market

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 39 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.Implanet.com.

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005476/en/

IMPLANET

Ludovic Lastennet, CEO

David Dieumegard, CFO

Tél. : +33 (0)5 57 99 55 55

investors@Implanet.com

NewCap

Investor Relations

Mathilde Bohin

Nicolas Fossiez

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

NewCap

Media Relations

Arthur Rouillé

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

Source: Implanet

FAQ

What key decisions were made at IMPLANET's Annual General Meeting on June 9, 2022?

All resolutions proposed at IMPLANET's Annual General Meeting were adopted.

What are the upcoming financial events for IMPLANET?

IMPLANET plans to announce H1 2022 revenue on July 11, 2022, and H1 2022 results on September 20, 2022.

What was IMPLANET's revenue in 2021?

IMPLANET recorded a consolidated revenue of €6.1 million in 2021.

What products does IMPLANET specialize in?

IMPLANET specializes in high-quality vertebral implants, notably their JAZZ® product.

What regulatory approvals does IMPLANET's JAZZ® product have?

The JAZZ® product has received FDA clearance, a CE mark in Europe, and ANVISA approval in Brazil.